CANSEARCH RESEARCH GRANT 2024 ("CANCURE FOR KIDS")

PROJECT DESCRIPTION

PROJECT TITLE Use Times New Roman, 12 point font throughout this form.

PROJECT TYPE Please tick all appropriate options for your study	
Pre-clinical Study: ☐ Yes ☐ No It includes, ☐ In-vitro ☐ In -vivo Cantonal Veterinary office approval: ☐ Yes ☐ No If yes, specify the Form B No:_____	Clinical study: ☐ Yes ☐ No It includes, ☐ Clinical data ☐ Biological sample Is it interventional: ☐Yes ☐No Ethical Committee approval: ☐Yes ☐No If yes, please specify the CER number:_____

PROJECT DETAILS	
New project or continuation:	
Project start date:	
Duration in months:	

PRINCIPAL INVESTIGATOR	
Name:	Email Address:
Department:	Title:
Role:	
Related experience for proposed project role:	

CO-RESEARCHER	
Name:	Email Address:
Department:	Title:
Role:	
Related experience for proposed project role:	

CO-RESEARCHER	
Name:	Email Address:
Department:	Title:
Role:	
Related experience for proposed project role:	

CO-RESEARCHER	
Name:	Email Address:
Department:	Title:
Role:	
Related experience for proposed project role:	

CO-RESEARCHER	
Name:	Email Address:
Department:	Title:
Role:	
Related experience for proposed project role:	

EXCLUDED REVIEWERS

If you wish to exclude certain reviewers from the evaluation process, please provide their exact names, work affiliations, email addresses and brief reason for exclusion below.

EXCLUDED REVIEWER 1:

Name:	Email Address:
Department:	Institution:
Reason:	

EXCLUDED REVIEWER 2:

Name:	Email Address:
Department:	Institution:
Reason:	

EXCLUDED REVIEWER 3:

Name:	Email Address:
Department:	Institution:
Reason:	

FUNDING AMOUNT REQUESTED

Cost item	Year 1 (2023)	Year 2 (2024)	Total cost (CHF)
Expenses total (CHF)			

FUNDING AMOUNT REQUESTED AND ALREADY OBTAINED

Name of the organisation:	Amount:

FUNDING AMOUNT REQUESTED BUT NOT (YET) OBTAINED

Name of the organisation:	Amount:

1. SUMMARY OF THE PROJECT (= ABSTRACT)

Use Times New Roman, 12 point font, single spaced
Maximum 1 page

2. BRIEFLY DESCRIBE THE BACKGROUND AND THE CURRENT STATUS OF KNOWLEDGE (RESULTS ALREADY ACHIEVED) OF THE PROJECT

Use Times New Roman, 12 point font, single spaced
Maximum 2 pages

    a. Background of research of the project

    b. Current status of knowledge (results already achieved/known) of the project

3.   HYPOTHESIS OF THE PROJECT
Use Times New Roman, 12 point font, single spaced **Maximum 100 words**

4. OUTLINE THE PROJECT'S OBJECTIVES
Use Times New Roman, 12 point font, single spaced **Maximum 1 page**

5. OUTLINE THE METHODOLOGY TO BE USED TO CARRY OUT THE PROJECT
including if applicable:
biomarker study design, study population, sample size and power calculation, treatment plan/evaluation, tissue collection/handling/analysis, imaging collection/review/analysis, statistical analysis plans, number of patients involved in the study and identification of the beneficiaries

Use Times New Roman, 12 point font, single spaced
Maximum 2 pages

| 6.	**OUTLINE THE MILESTONES, KEY PERFORMANCE INDICATORS AND RISKS OF THE PROJECT**
	Please use a figure to show the milestones with actions and schedule

Use Times New Roman, 12 point font, single spaced
Maximum 2 pages

a. Milestones (with a figure, as the following example)

Tasks:

Biobank development
1   4   7   9

Clinical & genetic data collection
2 3   5   11

Germline DNA sequencing & analysis
12   14   15   16   18/19   21

Functional in vitro analysis
6   8   10   13   17   20

Schedule and milestones:

10/2017	04/2018	04/2019	04/2020	04/2021	03/2022

Before start:	First year:	Second year:	Third year:	Fourth year:
1 Establish structures with all involved collaborators for data exchange and analysis **2** Ethical approval GECCOS project **3** Training of clinical centers	**4** Finalization of all agreements between stakeholders of the Swiss childhood cancer data network (by 06/2018) **5** Data and DNA sample collection established, recruitment open at all participating centers (by 06/2018) **6** Establishment of appropriate cell lines for *in vitro* assays (by 06/2018) **7** Fully functional data exchange (by 12/2018) **8** Sensitivity testing of cell lines to lung toxic treatment and resistant cell line creation (by 12/2018)	**9** Publication writing of workflow establishment and its evaluation (by 06/2019) **10** *In vitro* gene expression analysis (by 06/2019) **11** Full clinical dataset and all DNA samples collected (n=896; by 12/2019) **12** Germline DNA whole-genome sequencing completed (by 03/2020) **13** *In vitro* sensitivity to lung toxic treatment after knockout/ silencing of candidate genes (by 04/2020)	**14** Genotyping and variant calling (by 09/2020) **15** Clinical dataset cleaning and genotype-phenotype association analysis (by 12/2020) **16** Replication analyses in SJLIFE cohort (by 03/2021) **17** Cell apoptosis testing assays on cells after knockout/ silencing of candidate genes (by 04/2021)	**18** DNA sampling established for new patients (n=250/y; by 06/2021) **19** Publication writing GECCOS project (by 06/2021) **20** Publication writing functional studies (by 12/2021) **21** DNA collection completed in remaining cohort of Swiss CCS (n=6'916, by 03/2022)

b. Key performance indicators (e.g. number of samples collected and number of samples analysed, collaborations to come, follow-up of the publications, funding obtained, etc.)

c. Risks (not to achieve the project's objectives, but risks for the patient/family) and measures to be taken to tackle them

7. BRIEFLY DESCRIBE THE EXPECTED RESULTS AND IMPACTS / SIGNIFICANCE

Use Times New Roman, 12 point font, single spaced
Maximum 1 page

8.   REFERENCES LIST
Use Times New Roman, 12 point font, single spaced